Evaluation of the Cost-Effectiveness of Vaccination of Children with 5-valent Vaccine against Rotavirus Infection in the Russian Federation

One of the main causes of the incidence of intestinal infections in children under 5 years infection is rotavirus. Vaccines against rotavirus infection substantially reduce morbidity.The objective of this study is to analyze cost-effectiveness of vaccination of children with 5-valent vaccine against...

Full description

Saved in:
Bibliographic Details
Main Authors: Alla V. Rudakova, Susanna M. Kharit, Aleksandr T. Podkolzin, Aleksandr N. Uskov, Yurii V. Lobzin
Format: Article
Language:Russian
Published: Union of pediatricians of Russia 2018-01-01
Series:Педиатрическая фармакология
Subjects:
Online Access:https://www.pedpharma.ru/jour/article/view/1579
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1839587062270918656
author Alla V. Rudakova
Susanna M. Kharit
Aleksandr T. Podkolzin
Aleksandr N. Uskov
Yurii V. Lobzin
author_facet Alla V. Rudakova
Susanna M. Kharit
Aleksandr T. Podkolzin
Aleksandr N. Uskov
Yurii V. Lobzin
author_sort Alla V. Rudakova
collection DOAJ
description One of the main causes of the incidence of intestinal infections in children under 5 years infection is rotavirus. Vaccines against rotavirus infection substantially reduce morbidity.The objective of this study is to analyze cost-effectiveness of vaccination of children with 5-valent vaccine against rotavirus infection in the Russian Federation.Methods. The evaluation was carried out using modelling on the  basis of published data on the effectiveness of vaccines and  epidemiological data for the Russian Federation. In the base case analysis was performed from the position of the society as a  whole. During the sensitivity analysis cost-effectiveness was also  evaluated from the position of the health system. The evaluation was performed on the period of survival of vaccinated children. The costof therapy corresponded to the rates of OMS in St. Petersburg in 2017, the price of 1 dose of vaccine accounted for in the calculationof 1450 rubles. Costs and life expectancy with regard to quality were discounted at 3.5% per year.Results. Taking into account the accepted assumptions, the mass  vaccination will prevent the vaccinated population in the average  4675 RVI outpatient cases and 1732 RVI cases requiring  hospitalization per 100 thousand children the first year of life, with  90% coverage. In unvaccinated populations will be prevented 4128  outpatient cases and 1212 RVI cases requiring hospitalization. The  projected amount of avoided costs in general — 2.94 thousand RUB  per 1 child (54% in the vaccinated cohort, 46% in unvaccinated  population). Cost-effectiveness will be in the evaluation from the  perspective of society as a whole of 260.1 thousand RUB counting on an quality adjusted life year (QALY), and the evaluation from the perspective of the health system — 653.0 thousand roubles/QALY. Thus, in both cases, costeffectiveness of rotavirus vaccination per 1  QALY will not exceed the generally accepted threshold willingness-to- pay equal to three times the gross domestic product in Russia (2016  — 1.76 million RUB). The projected economic efficiency of selective  vaccination 4.94 times lower than one of mass vaccination.Conclusions. Mass vaccination of children with 5-valent vaccine against RVI will not only reduce the incidence in the Russian  Federation, but, given the adopted assumptions, may also be  considered as a cost-effective intervention.
format Article
id doaj-art-a7e92093ad9c45d8b79917f4d7b53df1
institution Matheson Library
issn 1727-5776
2500-3089
language Russian
publishDate 2018-01-01
publisher Union of pediatricians of Russia
record_format Article
series Педиатрическая фармакология
spelling doaj-art-a7e92093ad9c45d8b79917f4d7b53df12025-08-03T19:21:27ZrusUnion of pediatricians of RussiaПедиатрическая фармакология1727-57762500-30892018-01-0114650150710.15690/pf.v14i6.18331542Evaluation of the Cost-Effectiveness of Vaccination of Children with 5-valent Vaccine against Rotavirus Infection in the Russian FederationAlla V. Rudakova0Susanna M. Kharit1Aleksandr T. Podkolzin2Aleksandr N. Uskov3Yurii V. Lobzin4Scientific Research Institute of Children’s Infections St. Petersburg Chemical Pharmaceutical AcademyScientific Research Institute of Children’s InfectionsFederal Budget Institute of Science Central Research Institute for EpidemiologyScientific Research Institute of Children’s InfectionsScientific Research Institute of Children’s Infections North-Western State Medical University named after I.I. MechnikovOne of the main causes of the incidence of intestinal infections in children under 5 years infection is rotavirus. Vaccines against rotavirus infection substantially reduce morbidity.The objective of this study is to analyze cost-effectiveness of vaccination of children with 5-valent vaccine against rotavirus infection in the Russian Federation.Methods. The evaluation was carried out using modelling on the  basis of published data on the effectiveness of vaccines and  epidemiological data for the Russian Federation. In the base case analysis was performed from the position of the society as a  whole. During the sensitivity analysis cost-effectiveness was also  evaluated from the position of the health system. The evaluation was performed on the period of survival of vaccinated children. The costof therapy corresponded to the rates of OMS in St. Petersburg in 2017, the price of 1 dose of vaccine accounted for in the calculationof 1450 rubles. Costs and life expectancy with regard to quality were discounted at 3.5% per year.Results. Taking into account the accepted assumptions, the mass  vaccination will prevent the vaccinated population in the average  4675 RVI outpatient cases and 1732 RVI cases requiring  hospitalization per 100 thousand children the first year of life, with  90% coverage. In unvaccinated populations will be prevented 4128  outpatient cases and 1212 RVI cases requiring hospitalization. The  projected amount of avoided costs in general — 2.94 thousand RUB  per 1 child (54% in the vaccinated cohort, 46% in unvaccinated  population). Cost-effectiveness will be in the evaluation from the  perspective of society as a whole of 260.1 thousand RUB counting on an quality adjusted life year (QALY), and the evaluation from the perspective of the health system — 653.0 thousand roubles/QALY. Thus, in both cases, costeffectiveness of rotavirus vaccination per 1  QALY will not exceed the generally accepted threshold willingness-to- pay equal to three times the gross domestic product in Russia (2016  — 1.76 million RUB). The projected economic efficiency of selective  vaccination 4.94 times lower than one of mass vaccination.Conclusions. Mass vaccination of children with 5-valent vaccine against RVI will not only reduce the incidence in the Russian  Federation, but, given the adopted assumptions, may also be  considered as a cost-effective intervention.https://www.pedpharma.ru/jour/article/view/1579rotavirus infectionvaccinationcost-effectiveness
spellingShingle Alla V. Rudakova
Susanna M. Kharit
Aleksandr T. Podkolzin
Aleksandr N. Uskov
Yurii V. Lobzin
Evaluation of the Cost-Effectiveness of Vaccination of Children with 5-valent Vaccine against Rotavirus Infection in the Russian Federation
Педиатрическая фармакология
rotavirus infection
vaccination
cost-effectiveness
title Evaluation of the Cost-Effectiveness of Vaccination of Children with 5-valent Vaccine against Rotavirus Infection in the Russian Federation
title_full Evaluation of the Cost-Effectiveness of Vaccination of Children with 5-valent Vaccine against Rotavirus Infection in the Russian Federation
title_fullStr Evaluation of the Cost-Effectiveness of Vaccination of Children with 5-valent Vaccine against Rotavirus Infection in the Russian Federation
title_full_unstemmed Evaluation of the Cost-Effectiveness of Vaccination of Children with 5-valent Vaccine against Rotavirus Infection in the Russian Federation
title_short Evaluation of the Cost-Effectiveness of Vaccination of Children with 5-valent Vaccine against Rotavirus Infection in the Russian Federation
title_sort evaluation of the cost effectiveness of vaccination of children with 5 valent vaccine against rotavirus infection in the russian federation
topic rotavirus infection
vaccination
cost-effectiveness
url https://www.pedpharma.ru/jour/article/view/1579
work_keys_str_mv AT allavrudakova evaluationofthecosteffectivenessofvaccinationofchildrenwith5valentvaccineagainstrotavirusinfectionintherussianfederation
AT susannamkharit evaluationofthecosteffectivenessofvaccinationofchildrenwith5valentvaccineagainstrotavirusinfectionintherussianfederation
AT aleksandrtpodkolzin evaluationofthecosteffectivenessofvaccinationofchildrenwith5valentvaccineagainstrotavirusinfectionintherussianfederation
AT aleksandrnuskov evaluationofthecosteffectivenessofvaccinationofchildrenwith5valentvaccineagainstrotavirusinfectionintherussianfederation
AT yuriivlobzin evaluationofthecosteffectivenessofvaccinationofchildrenwith5valentvaccineagainstrotavirusinfectionintherussianfederation